Table 3.

Liebowitz social anxiety total scores, severity categorization and changes in total score^a

	Placebo (n = 4)		MDMA (n = 8)c
Primary efficacy variable LSAS total score, mean (SD)
Baseline	83.3 (11.9)		91.8 (15.8)
Primary endpoint	64.0 (13.3)		46.4 (15.2)
Changeb	− 19.3 (18.8)		− 44.1 (14.8)
P valueb		0.037
Primary endpoint, no. (%) LSAS 20-point reduction
Yes	2 (50.0)		6 (85.7)
No	2 (50.0)		1 (14.3)
LSAS severity categoriesd
Baseline
Marked	2 (50.0)		2 (25.0)
Severe	2 (50.0)		3 (37.5)
Very severe	0		3 (37.5)
Primary endpoint
Normal	2 (50.0)		5 (71.4)
Moderate	0		1 (12.5)
Marked	2 (50.0)		1 (12.5)
Change baseline to primary endpoint
No change	1 (25.0)		0
Reduction of one level	1 (25.0)		0
Reduction of two levels	1 (25.0)		4 (57.1)
Reduction of three levels	1 (25.0)		2 (28.6)
Reduction of four levels	0		1 (12.5)
LSAS total score, mean (SD)
Baseline	83.3 (11.9)		91.8 (15.8)
6-month follow-up	60.0 (17.4)		42.9 (20.4)
Changeb	− 23.3 (18.0)		− 47.7 (14.7)
P valueb		0.036

Abbreviations: LSAS, Liebowitz Social Anxiety Scale; N, number of participants

^aOutcomes are based on intent-to-treat set

^bChange from baseline

^cN = 7 in MDMA group after baseline

^dSeverity categories defined as LSAS total scores ranging from 0 to 54 (normal), 55–65 (moderate), 66–80 (marked), 81–95 (severe), 96–200 (very severe)